中文产业新闻精选评分72Chinese source
依沃西单抗对比帕博利珠单抗在PD-L1阳性晚期非小细胞肺癌一线治疗中显示生存优势
中位总生存期突破30个月！国产双抗药物依沃西单抗头对头击败「全球药王」，晚期肺癌治疗天花板再迎突破
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.
中位总生存期突破30个月！国产双抗药物依沃西单抗头对头击败「全球药王」，晚期肺癌治疗天花板再迎突破
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.